Rasmus Juul Kildemoes (Rasmus J Kildemoes)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 10

Top Topics

Placebo Controlled

Top Venues

Clinical pharmacokinetics

European journal of endocrinology

The Journal of clinical endocrinology and metabolism

Journal of the Endocrine Society

This page only lists publications with an associated author ORCID identifier.

Publications

Anders Juul, Philippe F Backeljauw, Michael Højby Rasmussen, Jan Frystyk, Masanobu Kawai, Rasmus Juul Kildemoes, Anders Krogh Lemminger, Agnès Linglart, Nehama Zuckerman Levin, Reiko Horikawa
Somapacitan in Children Born SGA: 52-week Efficacy, Safety, and IGF-I Response Results from the Phase 2 REAL5 Study. The Journal of clinical endocrinology and metabolism (2024)
Sarah Louise Dombernowsky, Birgitte Bentz Damholt, Michael Højby Rasmussen, Claus Sværke, Rasmus Juul Kildemoes
Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial. Clinical pharmacokinetics 63 (7) (2024)
Sarah Louise Dombernowsky, Birgitte Bentz Damholt, Michael Højby Rasmussen, Claus Sværke, Rasmus Juul Kildemoes
Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial. Clinical pharmacokinetics (2024)
Sarah Louise Dombernowsky, Birgitte Bentz Damholt, Michael Højby Rasmussen, Claus Sværke, Rasmus Juul Kildemoes
Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial. Clinical pharmacokinetics 63 (7) (2024)
Sarah Louise Dombernowsky, Birgitte Bentz Damholt, Michael Højby Rasmussen, Claus Sværke, Rasmus Juul Kildemoes
Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial. Clinical pharmacokinetics 63 (7) (2024)
Sarah Louise Dombernowsky, Birgitte Bentz Damholt, Michael Højby Rasmussen, Claus Sværke, Rasmus Juul Kildemoes
Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial. Clinical pharmacokinetics 63 (7) (2024)
Rasmus Juul Kildemoes, Philippe F Backeljauw, Michael Højby Rasmussen, Joanne C Blair, Bradley S Miller, Jun Mori, Yassine K Lyauk
Model-Based Analysis of IGF-I Response, Dosing, and Monitoring for Once-Weekly Somapacitan in Children With GH Deficiency. Journal of the Endocrine Society 7 (11) (2023)
Rasmus Juul Kildemoes, Christian Hollensen, Beverly M K Biller, Gudmundur Johannsson, Yutaka Takahashi, Michael Højby Rasmussen
Dose-exposure-IGF-I response of once-weekly somapacitan in adults with GH deficiency. European journal of endocrinology 187 (1) (2022)
Theodoros Papathanasiou, Henrik Agersø, Birgitte Bentz Damholt, Michael Højby Rasmussen, Rasmus Juul Kildemoes
Population Pharmacokinetics and Pharmacodynamics of Once-Daily Growth Hormone Norditropin® in Children and Adults. Clinical pharmacokinetics 60 (9) (2021)
Rune Viig Overgaard, Andrea Navarria, Steen H Ingwersen, Tine A Bækdal, Rasmus Juul Kildemoes
Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. Clinical pharmacokinetics 60 (10) (2021)